Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
International Journal of Molecular Sciences · 19.03.2023 · 24 (6) · 5840
DOI: 10.3390/ijms24065840 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.03.2023. Verfasst von Daniele Lavacchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Benzofurans, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The management of patients with metastatic colorectal cancer (mCRC) has the continuum of care as the treatment paradigm. To date, trifluridine/tipiracil, a biochemically modulated fluoropyrimidine, and regorafenib, a multi-kinase inhibitor, remain the main options for the majority of patients who progressed to standard doublet- or triplet-based chemotherapies, although a tailored approach could be indicated in certain circumstances. Being highly selective for vascular endothelial growth factor receptor (VEGFR)-1, -2 and -3, fruquintinib demonstrated a strong anti-tumor activity in preclinical models and received approval from China’s National Medical Products Administration (NMPA) in 2018 for the treatment of patients with chemo-refractory mCRC. The approval was based on the results of the phase III FRESCO trial. Then, in order to overcome geographic differences in clinical practice, the FRESCO-2 trial was conducted in the US, Europe, Japan, and Australia. In a heavily pretreated patient population, the study met its primary endpoint, demonstrating an advantage of fruquintinib over a placebo in overall survival (OS). Here, we review the clinical development of fruquintinib and its perspectives in gastrointestinal cancers. Then, we discuss the introduction of fruquintinib in the continuum of care of CRC paying special attention to unmet needs, including the identification of cross-resistant and potentially susceptible populations, evaluation of radiological response, and identification of novel biomarkers of clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.
- Department of Health Science, University of Florence, 50139 Florence, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
- Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.
ORCID-Profile: Enrico Caliman, Serena Pillozzi
Zitieren
APA
Lavacchi, D., Roviello, G., Guidolin, A., Romano, S., Venturini, J., Caliman, E., Vannini, A., Giommoni, E., Pellegrini, E., Brugia, M., Pillozzi, S., & Antonuzzo, L. (2023). Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. International Journal of Molecular Sciences, 24(6), 5840. https://doi.org/10.3390/ijms24065840
Vancouver
Lavacchi D, Roviello G, Guidolin A, Romano S, Venturini J, Caliman E, et al. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. International Journal of Molecular Sciences. 2023;24(6):5840. doi:10.3390/ijms24065840
BibTeX
@article{Lavacchi2023,
author = {Lavacchi, Daniele and Roviello, Giandomenico and Guidolin, Alessia and Romano, Silvia and Venturini, Jacopo and Caliman, Enrico and Vannini, Agnese and Giommoni, Elisa and Pellegrini, Elisa and Brugia, Marco and Pillozzi, Serena and Antonuzzo, Lorenzo},
title = {Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5840},
doi = {10.3390/ijms24065840}
}
EUVIMED